Stem Cell Therapies for Retinal Degenerations

This approach holds promise for preserving and restoring vision in AMD, RP, and beyond.

By: Noah M. Heaps, BS, Maximilian D. Kong, BS, Aykut Demirkol, MD, Stephen H. Tsang, MD, PhD, Ingrid U. Scott, MD, MPH

Retinal Physician May 1, 2025 Vol 22, Issue May 2025 Page(s): 16-18

Clinical Scorecard: Stem Cell Therapies for Retinal Degenerations

Category	Detail
Condition	Retinal Degenerations (AMD, RP)
Key Mechanisms	Stem cell therapy aims to replace dysfunctional retinal cells, particularly retinal pigment epithelial (RPE) cells, to restore vision.
Target Population	Patients with age-related macular degeneration (AMD) and retinitis pigmentosa (RP).
Care Setting	Ophthalmology clinics and research institutions.

Stem cell therapy shows promise for treating previously incurable retinal diseases.
RPE cell replacement is a primary focus due to its role in photoreceptor health.
Clinical trials demonstrate safety and potential efficacy of stem cell implants.
CRISPR technology is utilized for genetic correction of patient-derived stem cells.
Immune rejection remains a challenge, with strategies being developed to minimize risks.

Identify retinal degeneration conditions such as AMD and RP through clinical evaluation and imaging.

Consider stem cell therapy as a treatment option for eligible patients with AMD and RP.

Regular follow-up with advanced imaging to assess integration and function of transplanted cells.

Patients with advanced retinal degenerations, particularly those with AMD and RP.

Utilization of patient-derived iPSCs and RPE cell transplants shows potential for vision restoration.

Employ immunosuppression regimens when using allogeneic stem cells to reduce rejection risk.
Utilize HLA-matched donors to enhance graft acceptance.
Conduct thorough preoperative assessments to determine patient eligibility for stem cell therapy.